Neurological complications of cancer immunotherapy
Open Access
- 1 June 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 97, 102189
Abstract
No abstract availableKeywords
Funding Information
- Meso Scale Diagnostics
This publication has 75 references indexed in Scilit:
- Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumabMuscle & Nerve, 2016
- CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatmentNeurology, 2016
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort StudyClinical Cancer Research, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanomaMultiple Sclerosis Journal, 2014
- Paraneoplastic neuropathy2013
- A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric NeuropathyJournal of Immunotherapy, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patientAnnals of Oncology, 2011
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy, 2010